A fast-acting antihypertensive drug!
Wei Kang stared at the prescription in front of him with burning eyes, feeling happy in his heart.
As we all know, hypertension is a common chronic disease in modern society and the main risk factor for cardiovascular and cerebrovascular diseases.
As age increases, the incidence of hypertension will gradually increase, and the incidence is very high over the age of 40.
The causes of high blood pressure are complex. Long-term mental stress, unreasonable dietary structure, such as high-salt, low-potassium, high-fat diet, alcohol abuse, smoking, etc., can all lead to elevated blood pressure.
Currently, the world's best-selling fast-acting antihypertensive drug is Renosil developed by Pfizer. It has been on the market for more than 20 years. It is one of the most prescribed high blood pressure drugs in the world and has been used more than 40 billion times worldwide.
Commonly used antihypertensive drugs mainly include sartans and dipines. Huoluoxi is a representative of dipine drugs.
Dipine antihypertensive drugs are fast and long-acting. It doesn't matter if the patient occasionally misses a dose, but the load on the kidneys will be relatively large.
It is a calcium ion antagonist that can inhibit the transmembrane entry of calcium ions into vascular smooth muscle and myocardium, thereby dilating blood vessels and lowering blood pressure.
Sartan antihypertensive drugs have fewer side effects but are metabolized faster, so patients cannot miss taking them. Moreover, the rate of blood pressure reduction is slower than that of dipinephrine drugs, and it is mainly used for long-term use to control blood pressure.
This is also an antagonist that acts on angiotensin receptors and can block the vasoconstrictive effect of angiotensin, thereby dilating blood vessels and lowering blood pressure.
Sartan-type antihypertensive drugs and primi-type antihypertensive drugs have similar target targets and each has its own advantages and disadvantages. However, they generally cannot be used together at the same time. Doctors need to use the drugs according to the specific conditions of the patient.
The new antihypertensive drug in front of Wei Kang is not the above common antihypertensive drugs, but it has a better antihypertensive effect.
Its medicinal principle is also different. It mainly regulates the channels of calcium ions and potassium ions, which not only inhibits the absorption of sodium ions, but also increases the potassium ion content in the body and keeps it in balance, thereby achieving the effect of lowering blood pressure and protecting blood vessels.
Not only can it quickly lower blood pressure and control blood pressure stably for a long time, but its side effects are much smaller than those of common antihypertensive drugs.
Therefore, it will not only replace dipine-type antihypertensive drugs such as Huoluoxi, but also Sartan-type antihypertensive drugs, becoming the first choice for all patients with hypertension.
There are 1.3 billion people suffering from hypertension in the world, and the market prospect is very broad. Antihypertensive drugs are also a battleground for major pharmaceutical companies. Every year, countless pharmaceutical companies are developing new antihypertensive drugs.
Weicome believes that this new antihypertensive drug will once again trigger a shock in the global antihypertensive drug market after it is introduced to the market.
As long as the price is not particularly high, it will surely sweep the global market in a few years.
It is somewhat impossible to directly occupy all the markets, because antihypertensive drugs are a relatively old and mature market, and many antihypertensive drugs have a history of more than ten or even twenty or thirty years.
Antihypertensive drugs are drugs that need to be taken for a long time and safety comes first. Most patients with hypertension will generally choose drugs that are safer and more reliable and have been tested in the market for a long time.
However, there is no problem in grabbing a piece of market share and gradually cannibalizing the market of other pharmaceutical companies.
After reading this antihypertensive drug, he turned his attention to another specific antithrombotic drug.
Thrombus is mainly composed of insoluble fibrin, deposited platelets, blocked red blood cells and white blood cells.
It can cause a series of symptoms such as varicose veins, swelling of the lower limbs, and difficulty breathing. In severe cases, it can also cause cerebral thrombosis, which can cause sudden death of a healthy ordinary person at any time.
Every year, there are countless stories in the news about people who died suddenly due to continuous overtime work.
Some people have vascular disease caused by high blood pressure, high blood sugar, and high blood lipids, which can lead to blood clots.
There are also some people who have injured the blood vessel wall after undergoing surgery.
Either way, they will take anti-thrombotic drugs.
This is a common disease among the elderly and people with high blood pressure.
An average of 20 million people worldwide are killed by cardiovascular and cerebrovascular diseases every year, of which one-third die from stroke (stroke). China is a country with a high incidence of stroke, with the number of deaths ranking first in the world. There are 1.5 million people.
That's why sales of antithrombotic drugs are so high.
There are many pharmaceutical companies around the world that produce anti-thrombotic drugs. Giants like Pfizer can sell billions of dollars in sales every year. Some small pharmaceutical companies can also sell anti-thrombotic drugs for tens of millions of dollars.
Moreover, antithrombotic drugs are also a very mature and ancient market, with a rich variety of drugs and many choices for patients.
However, when most people choose medicines, they still try to choose products from big brands, as their efficacy is guaranteed.
This is a market worth tens of billions of dollars, with huge profits, blockbuster drugs emerging one after another, and fierce competition among many giants.
The king of drugs in the field of anti-thrombosis is apixaban, an intravenous anticoagulant developed by Bristol-Myers Squibb. Its global sales have exceeded US$10 billion seven years after it was launched.
Common antithrombotic drugs are mainly divided into anticoagulants, antiplatelet aggregation drugs, and thrombolytic drugs. There are differences among the three drugs, each with different mechanisms of action and used in different diseases.
Anticoagulants are often used to prevent venous thrombosis, and antiplatelet drugs are often used to prevent arterial thrombosis.
Thrombolytic drugs have a faster effect than anticoagulants, but have a greater risk of bleeding, so they often need to be used under the supervision of a doctor in the hospital.
This anti-thrombotic drug on hand by Wei Kang mainly prevents platelet aggregation and dissolves fibrin. It is extremely effective in preventing arterial thrombosis and dissolving thrombosis.
Extremely dangerous cardiovascular and cerebrovascular diseases such as stroke (stroke) and sudden myocardial infarction are all caused by arterial embolism, and are the applicable diseases of this new drug.
"Awesome! These are two god-level drugs. I can't wait to see the clinical effects!"
"If the clinical effects are really that good, they will definitely be two flagship drugs with annual sales exceeding 10 billion US dollars."
Wei Kang's eyes shone, as if he had seen two golden medicine kings waving to him.
He quickly assigned these seven prescriptions to his laboratory employees and began a series of subsequent developments.
Since antihypertensive drugs and antithrombotic drugs are long-term medications, the clinical requirements are very strict. They must start from the first clinical phase, and the number of people in each phase must be as large as possible.
Even after it is launched on the market, phase four clinical trials must continue to be carried out to monitor the side effects and long-term effects of the drug on patients at any time.
Previous anti-cancer drugs and AD specific drugs, because they were breakthrough innovative drugs, all followed the green fast-track application process, and it only took a few months from clinical to market.
As these two cardiovascular and cerebrovascular drugs are not considered breakthrough innovative drugs, they cannot go through the fast-track approval channel. They can only go all the way step by step. When they are approved and launched, it will probably be by the end of the year.
In short, this is a long-term process that takes a long time and consumes a lot of money.
Weikang finally realized the hard work and long process of traditional drug development.
Fortunately, several other drugs are not so troublesome.
Hair removal creams are ordinary cosmetics, and a Phase II clinical trial is enough to prove their effectiveness.
Scar removal cream is an over-the-counter medicine for external use. The clinical trial requirements are not strict and the marketing process is relatively simple.
Of course, it can be diluted and made into skin care products. I definitely scorn a cream like La Mer that claims to be able to remove scars.
Anti-allergic drugs are prescription drugs and need to undergo phase II and phase III clinical trials. The process should be very fast, and they can also be made into anti-allergic skin care products.
As for pesticides and veterinary drugs, they only need to be tested for safety and tested on animals. Compared with drugs for human use, the approval process is simple and fast.
I believe that within a few months, Sanqing will have several new drugs on the market.
82 Chinese website
